Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XM Isocitrate dehydrogenase (IDH) inhibitors
L01XM01 Enasidenib
D11044 Enasidenib mesylate (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
IDH2 Enzyme Inhibitors
Enasidenib
D11044 Enasidenib mesylate (USAN)
Drug groups [BR:br08330]
Unclassified
DG03328 Isocitrate dehydrogenase inhibitor
DG02837 Enasidenib
D11044 Enasidenib mesylate
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
IDH2* [HSA_VAR:3418v1]
D11044 Enasidenib mesylate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11044
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11044
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11044
Drug groups [BR:br08330]
Unclassified
DG03328 Isocitrate dehydrogenase inhibitor
DG02837 Enasidenib